Black Diamond Therapeutics Inc logo

BDTX - Black Diamond Therapeutics Inc News Story

$12.32 0.1  0.7%

Last Trade - 9:00pm

Small Cap
Market Cap £323.7m
Enterprise Value £115.5m
Revenue £n/a
Position in Universe 3778th / 6938

Black Diamond Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Sat 8th May, 2021 8:13am
* Black Diamond Therapeutics Inc  BDTX.OQ  reported a quarterly
adjusted loss of 84 cents​​ per share for the quarter ended
in March. The mean expectation of six analysts for the quarter
was for a loss of 68 cents per share.
* Revenue was $0.00​​;  analysts expected $0.00.
* Black Diamond Therapeutics Inc's reported EPS for the quarter
was a loss of 84 cents​.
* The mean earnings estimate of analysts had fallen by
about 8.2% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Black Diamond Therapeutics Inc shares had risen by 5.3% this
quarter and lost 20.3% so far this year.
* The company reported a quarterly loss of $30.3 million.
* Wall Street's median 12-month price target for Black Diamond
Therapeutics Inc is $52.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 8 at 07:13 a.m. GMT. ​All
figures in US Dollars.​
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.